
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/930582/publications.pdf Version: 2024-02-01



ΜΑΡΟ ΡΙΒΑ

#	Article	IF	CITATIONS
1	Trackability of distal access catheters: an in vitro quantitative evaluation of navigation strategies. Journal of NeuroInterventional Surgery, 2023, 15, 496-501.	3.3	3
2	Direct to angiosuite strategy versus standard workflow triage for endovascular therapy: systematic review and meta-analysis. Journal of NeuroInterventional Surgery, 2023, 15, e17-e25.	3.3	3
3	Mechanical thrombectomy with a novel device: initial clinical experience with the ANA thrombectomy device. Journal of Neuroradiology, 2022, 49, 324-328.	1.1	5
4	Endovascular therapy with or without intravenous thrombolysis in acute stroke with tandem occlusion. Journal of NeuroInterventional Surgery, 2022, 14, 314-320.	3.3	25
5	Monocyte-to-Lymphocyte Ratio in Clot Analysis as a Marker of Cardioembolic Stroke Etiology. Translational Stroke Research, 2022, 13, 949-958.	4.2	9
6	Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion. JAMA Neurology, 2022, 79, 22.	9.0	137
7	The Role of Vascular Imaging atReferral Centers in the Drip and Ship Paradigm. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106209.	1.6	2
8	Clinical Results of the Advanced Neurovascular Access Catheter System Combined With a Stent Retriever in Acute Ischemic Stroke (SOLONDA). Stroke, 2022, 53, 2211-2219.	2.0	2
9	REACT Aspiration Catheters: Clinical Experience and Technical Considerations. Neurointervention, 2022, 17, 70-77.	0.8	6
10	Automated Perfusion Calculations vs. Visual Scoring of Collaterals and CBV-ASPECTS. Clinical Neuroradiology, 2021, 31, 499-506.	1.9	19
11	Benefit of endovascular thrombectomy for M2 middle cerebral artery occlusion in the ARISE II study. Journal of NeuroInterventional Surgery, 2021, 13, 779-783.	3.3	24
12	Clinical improvement within 24 hours from mechanical thrombectomy as a predictor of long-term functional outcome in a multicenter population-based cohort of patients with ischemic stroke. Journal of NeuroInterventional Surgery, 2021, 13, 119-123.	3.3	8
13	Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment: Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention. European Heart Journal, 2021, 42, 298-307.	2.2	18
14	Leptomeningeal Collateral Flow Modifies Endovascular Treatment Efficacy on Large-Vessel Occlusion Strokes. Stroke, 2021, 52, 299-303.	2.0	18
15	European Multicenter Study of ET-COVID-19. Stroke, 2021, 52, 31-39.	2.0	25
16	Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome. Stroke, 2021, 52, 132-141.	2.0	36
17	Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry. International Journal of Stroke, 2021, 16, 437-447.	5.9	114
18	Suction force rather than aspiration flow correlates with recanalization in hard clots: an in vitro study model. Journal of NeuroInterventional Surgery, 2021, 13, 1157-1161.	3.3	6

#	Article	IF	CITATIONS
19	Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry. BMC Neurology, 2021, 21, 43.	1.8	47
20	Bottlenecks in the Acute Stroke Care System during the COVID-19 Pandemic in Catalonia. Cerebrovascular Diseases, 2021, 50, 551-559.	1.7	10
21	Strengths and Challenges of Secretory Ribonucleases as AntiTumor Agents. Pharmaceutics, 2021, 13, 82.	4.5	7
22	Response by Olivé Gadea and Ribo to Letter Regarding Article, "Deep Learning Based Software to Identify Large Vessel Occlusion on Noncontrast Computed Tomography― Stroke, 2021, 52, e63.	2.0	1
23	Defining a Target Population to Effectively Test a Neuroprotective Drug. Stroke, 2021, 52, 505-510.	2.0	3
24	Single nucleotide variations in <i>ZBTB46</i> are associated with post-thrombolytic parenchymal haematoma. Brain, 2021, 144, 2416-2426.	7.6	10
25	The Selectivity for Tumor Cells of Nuclear-Directed Cytotoxic RNases Is Mediated by the Nuclear/Cytoplasmic Distribution of p27KIP1. Molecules, 2021, 26, 1319.	3.8	1
26	Blood Biomarkers to Differentiate Ischemic and Hemorrhagic Strokes. Neurology, 2021, 96, e1928-e1939.	1.1	34
27	Abstract P134: Economic and Clinical Model for Direct Transfer to Angiosuite Protocol Development. Stroke, 2021, 52, .	2.0	0
28	Catheter tip distensibility substantially influences the aspiration force of thrombectomy devices. Journal of NeuroInterventional Surgery, 2021, , neurintsurg-2021-017487.	3.3	4
29	SELECTion criteria for large core trials: dogma or data?. Journal of NeuroInterventional Surgery, 2021, 13, 500-504.	3.3	17
30	Benchmarking the Extent and Speed of Reperfusion: First Pass TICI 2c-3 Is a Preferred Endovascular Reperfusion Endpoint. Frontiers in Neurology, 2021, 12, 669934.	2.4	19
31	Ischemic Core Overestimation on Computed Tomography Perfusion. Stroke, 2021, 52, 1751-1760.	2.0	39
32	RP11-362K2.2:RP11-767I20.1 Genetic Variation Is Associated with Post-Reperfusion Therapy Parenchymal Hematoma. A GWAS Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 3137.	2.4	6
33	Response to letter: How much will a catheter tip expand in aspiration thrombectomy?. Journal of NeuroInterventional Surgery, 2021, , neurintsurg-2021-017919.	3.3	0
34	A Nuclear-Directed Ribonuclease Variant Targets Cancer Stem Cells and Inhibits Migration and Invasion of Breast Cancer Cells. Cancers, 2021, 13, 4350.	3.7	2
35	Direct to Angiography vs Repeated Imaging Approaches in Transferred Patients Undergoing Endovascular Thrombectomy. JAMA Neurology, 2021, 78, 916.	9.0	33
36	Assessment of Optimal Patient Selection for Endovascular Thrombectomy Beyond 6 Hours After Symptom Onset. JAMA Neurology, 2021, 78, 1064.	9.0	42

#	Article	IF	CITATIONS
37	Direct to Angiography Suite Without Stopping for Computed Tomography Imaging for Patients With Acute Stroke. JAMA Neurology, 2021, 78, 1099.	9.0	65
38	Serial ASPECTS in the DAWN Trial. Stroke, 2021, 52, 3318-3324.	2.0	3
39	Endovascular Therapy of Anterior Circulation Tandem Occlusions. Stroke, 2021, 52, 3097-3105.	2.0	48
40	Health economic impact of first-pass success among patients with acute ischemic stroke treated with mechanical thrombectomy: a United States and European perspective. Journal of NeuroInterventional Surgery, 2021, 13, 1117-1123.	3.3	16
41	Predictors of unfavorable outcomes despite substantial reperfusion: Insights from Analysis of Revascularization in Ischemic Stroke With EmboTrap II Study. Interventional Neuroradiology, 2021, , 159101992110515.	1.1	0
42	Direct Transfer to Angiosuite in Acute Stroke. Neurology, 2021, 97, S34-S41.	1.1	4
43	ANCD thrombectomy device: in vitro evaluation. Journal of NeuroInterventional Surgery, 2020, 12, 77-81.	3.3	17
44	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. European Journal of Preventive Cardiology, 2020, 27, 682-692.	1.8	15
45	Clinical and neuroimaging criteria to improve the workflow in transfers for endovascular treatment evaluation. International Journal of Stroke, 2020, 15, 988-994.	5.9	8
46	Impact of Periprocedural and Technical Factors and Patient Characteristics on Revascularization and Outcome in the DAWN Trial. Stroke, 2020, 51, 247-253.	2.0	18
47	Spontaneous systolic blood pressure drop early after mechanical thrombectomy predicts dramatic neurological recovery in ischaemic stroke patients. European Stroke Journal, 2020, 5, 362-369.	5.5	8
48	COVID-19 and Stroke: Incidence and Etiological Description in a High-Volume Center. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105225.	1.6	40
49	Deep Learning Based Software to Identify Large Vessel Occlusion on Noncontrast Computed Tomography. Stroke, 2020, 51, 3133-3137.	2.0	47
50	Vascular Occlusion Evolution in Endovascular Reperfusion Candidates Transferred from Primary to Comprehensive Stroke Centers. Cerebrovascular Diseases, 2020, 49, 550-555.	1.7	7
51	Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel. International Journal of Stroke, 2020, 15, 540-554.	5.9	179
52	Time Matters. Stroke, 2020, 51, 1766-1771.	2.0	21
53	Management of acute ischemic stroke in patients with COVID-19 infection: Insights from an international panel. American Journal of Emergency Medicine, 2020, 38, 1548.e5-1548.e7.	1.6	40
54	Computed Tomography Perfusion After Thrombectomy. Stroke, 2020, 51, 1736-1742.	2.0	45

#	Article	IF	CITATIONS
55	Screening of Embolic Sources by Point-of-Care Ultrasound in the Acute Phase of Ischemic Stroke. Ultrasound in Medicine and Biology, 2020, 46, 2173-2180.	1.5	3
56	Impact of Antiplatelet Therapy During Endovascular Therapy for Tandem Occlusions. Stroke, 2020, 51, 1522-1529.	2.0	46
57	Sudden Recanalization. Stroke, 2020, 51, 1313-1316.	2.0	19
58	Preclinical evaluation of the ANCD thrombectomy device: safety and efficacy in a swine clot model. Journal of NeuroInterventional Surgery, 2020, 12, 1008-1013.	3.3	6
59	Primary endovascular treatment for acute ischemic stroke in teenage patients: a short case series. Neuroradiology, 2020, 62, 851-860.	2.2	2
60	The Value of Transcranial Doppler Sonography in Hyperperfusion Syndrome after Carotid Artery Stenting: A Nationwide Prospective Study. Journal of Stroke, 2020, 22, 254-257.	3.2	3
61	Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA. Neurology, 2019, 93, e851-e863.	1.1	10
62	Noncontrast Computed Tomography Alberta Stroke Program Early CT Score May Modify Intra-Arterial Treatment Effect in DAWN. Stroke, 2019, 50, 2404-2412.	2.0	17
63	Endovascular Treatment of Acute Stroke. Stroke, 2019, 50, 2612-2618.	2.0	42
64	Outcome in Direct Versus Transfer Patients in the DAWN Controlled Trial. Stroke, 2019, 50, 2163-2167.	2.0	14
65	Mechanical thrombectomy for basilar artery occlusion: efficacy, outcomes, and futile recanalization in comparison with the anterior circulation. Journal of NeuroInterventional Surgery, 2019, 11, 1174-1180.	3.3	106
66	Benefit of Endovascular Thrombectomy by Mode of Onset. Stroke, 2019, 50, 3141-3146.	2.0	17
67	Genome-Wide Association Study of White Blood Cell Counts in Patients With Ischemic Stroke. Stroke, 2019, 50, 3618-3621.	2.0	13
68	SEIMLESS: Simultaneous Extracranial, Intracranial Management of (tandem) LESsions in Stroke. Journal of NeuroInterventional Surgery, 2019, 11, 879-883.	3.3	7
69	Association of statin pretreatment with collateral circulation and final infarct volume in acute ischemic stroke patients: A meta-analysis. Atherosclerosis, 2019, 282, 75-79.	0.8	23
70	Association of Time From Stroke Onset to Groin Puncture With Quality of Reperfusion After Mechanical Thrombectomy. JAMA Neurology, 2019, 76, 405.	9.0	133
71	Emergent Carotid Stenting Plus Thrombectomy After Thrombolysis in Tandem Strokes. Stroke, 2019, 50, 2250-2252.	2.0	54
79	Farmalarm Stroka 2019 50 1819 1824	2.0	91

2.0 31

#	Article	lF	CITATIONS
73	When to Stop. Stroke, 2019, 50, 1781-1788.	2.0	97
74	Transfer to the Local Stroke Center versus Direct Transfer to Endovascular Center of Acute Stroke Patients with Suspected Large Vessel Occlusion in the Catalan Territory (RACECAT): Study protocol of a cluster randomized within a cohort trial. International Journal of Stroke, 2019, 14, 734-744.	5.9	63
75	Periprocedural Heparin During Endovascular Treatment of Tandem Lesions in Patients with Acute Ischemic Stroke: A Propensity Score Analysis from TITAN Registry. CardioVascular and Interventional Radiology, 2019, 42, 1160-1167.	2.0	13
76	Clinical Predictors of Hyperperfusion Syndrome Following Carotid Stenting. JACC: Cardiovascular Interventions, 2019, 12, 873-882.	2.9	17
77	Procedural approaches and angiographic signs predicting first-pass recanalization in patients treated with mechanical thrombectomy for acute ischaemic stroke. Interventional Neuroradiology, 2019, 25, 491-496.	1.1	21
78	Predictors of response to endovascular treatment of posterior circulation stroke. European Journal of Radiology, 2019, 116, 219-224.	2.6	6
79	Effect of extracranial lesion severity on outcome of endovascular thrombectomy in patients with anterior circulation tandem occlusion: analysis of the TITAN registry. Journal of NeuroInterventional Surgery, 2019, 11, 970-974.	3.3	25
80	Mechanical Thrombectomy in Ischemic Stroke Patients With Alberta Stroke Program Early Computed Tomography Score 0–5. Stroke, 2019, 50, 880-888.	2.0	100
81	Outcome, efficacy and safety of endovascular thrombectomy in ischaemic stroke according to time to reperfusion: data from a multicentre registry. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641983570.	3.5	14
82	Head or Neck First? Speed and Rates of Reperfusion in Thrombectomy for Tandem Large Vessel Occlusion Strokes. Interventional Neurology, 2019, 8, 92-100.	1.8	20
83	Baseline ASPECTS and eâ€ASPECTS Correlation with Infarct Volume and Functional Outcome in Patients Undergoing Mechanical Thrombectomy. Journal of Neuroimaging, 2019, 29, 198-202.	2.0	42
84	Revalidation of the RACE scale after its regional implementation in Catalonia: a triage tool for large vessel occlusion. Journal of NeuroInterventional Surgery, 2019, 11, 751-756.	3.3	48
85	Mediation of the Relationship Between Endovascular Therapy and Functional Outcome by Follow-up Infarct Volume in Patients With Acute Ischemic Stroke. JAMA Neurology, 2019, 76, 194.	9.0	77
86	Clinical effect of successful reperfusion in patients presenting with NIHSS < 8: data from the BEYOND-SWIFT registry. Journal of Neurology, 2019, 266, 598-608.	3.6	14
87	<i>PATJ</i> Low Frequency Variants Are Associated With Worse Ischemic Stroke Functional Outcome. Circulation Research, 2019, 124, 114-120.	4.5	49
88	Abstract WP41: The NeVa Thrombectomy Device: Initial Clinical Experience. Stroke, 2019, 50, .	2.0	0
89	Abstract TP194: Farmalarm: A Mobile Application to Improve Stroke Awareness. Stroke, 2019, 50, .	2.0	0
90	Association of follow-up infarct volume with functional outcome in acute ischemic stroke: a pooled analysis of seven randomized trials. Journal of NeuroInterventional Surgery, 2018, 10, 1137-1142.	3.3	93

#	Article	IF	CITATIONS
91	Primary Results of the Multicenter ARISE II Study (Analysis of Revascularization in Ischemic Stroke) Tj ETQq1 1 (	).784314 r 2.0	gBT /Qverloc
92	Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke. Neurology, 2018, 90, e995-e1004.	1.1	48
93	Direct transfer to angiosuite to reduce door-to-puncture time in thrombectomy for acute stroke. Journal of NeuroInterventional Surgery, 2018, 10, 221-224.	3.3	72
94	Yield of atrial fibrillation detection with Textile Wearable Holter from the acute phase of stroke: Pilot study of Crypto-AF registry. International Journal of Cardiology, 2018, 251, 45-50.	1.7	46
95	Prehospital Systolic Blood Pressure Is Related to Intracerebral Hemorrhage Volume on Admission. Stroke, 2018, 49, 204-206.	2.0	23
96	Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. New England Journal of Medicine, 2018, 378, 11-21.	27.0	3,936
97	Construction of Highly Stable Cytotoxic Nuclear-Directed Ribonucleases. Molecules, 2018, 23, 3273.	3.8	2
98	Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance. OncoTargets and Therapy, 2018, Volume 11, 221-237.	2.0	11
99	Ghost Infarct Core and Admission Computed Tomography Perfusion: Redefining the Role of Neuroimaging in Acute Ischemic Stroke. Interventional Neurology, 2018, 7, 513-521.	1.8	69
100	Direct Transfer to Angio-Suite to Reduce Workflow Times and Increase Favorable Clinical Outcome. Stroke, 2018, 49, 2723-2727.	2.0	84
101	Predictors of Endovascular Treatment Among Stroke Codes Activated Within 6 Hours From Symptom Onset. Stroke, 2018, 49, 2116-2121.	2.0	12
102	Endovascular Thrombectomy for Mild Strokes: How Low Should We Go?. Stroke, 2018, 49, 2398-2405.	2.0	100
103	Structural Insights into Subunits Assembly and the Oxyester Splicing Mechanism of Neq pol Split Intein. Cell Chemical Biology, 2018, 25, 871-879.e2.	5.2	5
104	Carotid Stenting With Antithrombotic Agents and Intracranial Thrombectomy Leads to the Highest Recanalization Rate in Patients With Acute Stroke With Tandem Lesions. JACC: Cardiovascular Interventions, 2018, 11, 1290-1299.	2.9	129
105	Telestroke in Catalonia: Increasing Thrombolysis Rate and Avoiding Interhospital Transfers. Cerebrovascular Diseases, 2018, 46, 66-71.	1.7	19
106	Apoptin, A Versatile Protein with Selective Antitumor Activity. Current Medicinal Chemistry, 2018, 25, 3540-3559.	2.4	9
107	Insights into the mechanism of Apoptin's exquisitely selective anti-tumor action from atomic level characterization of its conformation and dynamics. Archives of Biochemistry and Biophysics, 2017, 614, 53-64.	3.0	3
108	Admission CT perfusion may overestimate initial infarct core: the ghost infarct core concept. Journal of NeuroInterventional Surgery, 2017, 9, 66-69.	3.3	126

#	Article	IF	CITATIONS
109	Prosthetic Valve Thrombosis in the Acute Phase of the Stroke: Relevance of Detection and Follow-Up. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1110-1113.	1.6	2
110	A truncated apoptin protein variant selectively kills cancer cells. Investigational New Drugs, 2017, 35, 260-268.	2.6	6
111	GRECOS Project (Genotyping Recurrence Risk of Stroke). Stroke, 2017, 48, 1147-1153.	2.0	23
112	Diffusion-weighted imaging or computerized tomography perfusion assessment with clinical mismatch in the triage of wake up and late presenting strokes undergoing neurointervention with Trevo (DAWN) trial methods. International Journal of Stroke, 2017, 12, 641-652.	5.9	168
113	Emergent Carotid Stenting After Thrombectomy in Patients With Tandem Lesions. Stroke, 2017, 48, 1126-1128.	2.0	29
114	Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial. Lancet Neurology, The, 2017, 16, 369-376.	10.2	74
115	Extensive deamidation of RNase A inhibits its oligomerization through 3D domain swapping. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 76-87.	2.3	4
116	Thrombectomy in Acute Stroke With Tandem Occlusions From Dissection Versus Atherosclerotic Cause. Stroke, 2017, 48, 3145-3148.	2.0	53
117	Geographic dissemination of endovascular stroke thrombectomy in Catalonia within the 2011–2015 period. European Stroke Journal, 2017, 2, 163-170.	5.5	5
118	Multiphase CT Angiography Improves Prediction of Intracerebral Hemorrhage Expansion. Radiology, 2017, 285, 932-940.	7.3	30
119	Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 308-320.	1.6	3
120	Influence of Hospital Type on Outcomes of Individuals Aged 80 and Older with Stroke Treated Using Intravenous Thrombolysis. Journal of the American Geriatrics Society, 2017, 65, E117-E122.	2.6	4
121	Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase. Oncotarget, 2017, 8, 11692-11707.	1.8	20
122	Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis. Journal of Circulating Biomarkers, 2016, 5, 184945441666879.	1.3	25
123	Access to Endovascular Treatment in Remote Areas. Stroke, 2016, 47, 1381-1384.	2.0	48
124	Combination of Thrombolysis and Statins in Acute Stroke Is Safe. Stroke, 2016, 47, 2870-2873.	2.0	58
125	Prehospital Scales to Identify Patients With Large Vessel Occlusion. Stroke, 2016, 47, 2877-2878.	2.0	19
126	Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet, The, 2016, 387, 1723-1731.	13.7	5,331

#	Article	IF	CITATIONS
127	Structural investigation of ribonuclease A conformational preferences using high pressure protein crystallography. Chemical Physics, 2016, 468, 53-62.	1.9	7
128	Association Between Time to Reperfusion and Outcome Is Primarily Driven by the Time From Imaging to Reperfusion. Stroke, 2016, 47, 999-1004.	2.0	113
129	Ischemic stroke outcome: A review of the influence of post-stroke complications within the different scenarios of stroke care. European Journal of Internal Medicine, 2016, 29, 9-21.	2.2	94
130	A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells. Oncotarget, 2016, 7, 18309-18324.	1.8	15
131	Pittsburgh Response to Endovascular therapy (PRE) score: optimizing patient selection for endovascular therapy for large vessel occlusion strokes. Journal of NeuroInterventional Surgery, 2015, 7, 783-788.	3.3	49
132	Mechanical Thrombectomy in and Outside the REVASCAT Trial. Stroke, 2015, 46, 3437-3442.	2.0	41
133	Endovascular treatment for M2 occlusions in the era of stentrievers: a descriptive multicenter experience. Journal of NeuroInterventional Surgery, 2015, 7, 234-237.	3.3	55
134	Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. New England Journal of Medicine, 2015, 372, 2296-2306.	27.0	4,059
135	Poor Collateral Circulation Assessed by Multiphase Computed Tomographic Angiography Predicts Malignant Middle Cerebral Artery Evolution After Reperfusion Therapies. Stroke, 2015, 46, 3149-3153.	2.0	50
136	Monitoring of Cortical Activity Postreperfusion. A Powerful Tool for Predicting Clinical Response Immediately After Recanalization. Journal of Neuroimaging, 2015, 25, 257-262.	2.0	5
137	Stroke Echoscan Protocol: A Fast and Accurate Pathway to Diagnose Embolic Strokes. Journal of Neuroimaging, 2015, 25, 365-369.	2.0	3
138	Maximal Admission Core Lesion Compatible With Favorable Outcome in Acute Stroke Patients Undergoing Endovascular Procedures. Stroke, 2015, 46, 2849-2852.	2.0	31
139	NURR1 Involvement in Recombinant Tissue-Type Plasminogen Activator Treatment Complications After Ischemic Stroke. Stroke, 2015, 46, 477-484.	2.0	14
140	Baseline National Institutes of Health Stroke Scale–Adjusted Time Window for Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke. Stroke, 2014, 45, 1059-1063.	2.0	58
141	Stentrievers versus other endovascular treatment methods for acute stroke: comparison of procedural results and their relationship to outcomes. Journal of NeuroInterventional Surgery, 2014, 6, 265-269.	3.3	18
142	Outcomes of a Contemporary Cohort of 536 Consecutive Patients With Acute Ischemic Stroke Treated With Endovascular Therapy. Stroke, 2014, 45, 1046-1052.	2.0	60
143	Doorâ€ŧoâ€Puncture: A Practical Metric for Capturing and Enhancing System Processes Associated With Endovascular Stroke Care, Preliminary Results From the Rapid Reperfusion Registry. Journal of the American Heart Association, 2014, 3, e000859.	3.7	60
144	Recanalization and Clinical Outcome of Occlusion Sites at Baseline CT Angiography in the Interventional Management of Stroke III Trial. Radiology, 2014, 273, 202-210.	7.3	141

#	Article	IF	CITATIONS
145	Functional Outcome After Primary Endovascular Therapy or IV Thrombolysis Alone for Stroke. An Observational, Comparative Effectiveness Study. Cerebrovascular Diseases, 2014, 38, 328-336.	1.7	10
146	Medical and Endovascular Treatment of Patients with Large Vessel Occlusion Presenting with Mild Symptoms: An Observational Multicenter Study. Cerebrovascular Diseases, 2014, 38, 418-424.	1.7	54
147	Fluorescent Molecular Peroxidation Products. Stroke, 2014, 45, 432-437.	2.0	10
148	Potential Blood Pressure Thresholds and Outcome in Acute Intracerebral Hemorrhage. European Neurology, 2014, 72, 203-208.	1.4	5
149	Transcervical access in acute ischemic stroke. Journal of NeuroInterventional Surgery, 2014, 6, 652-657.	3.3	61
150	Age-adjusted infarct volume threshold for good outcome after endovascular treatment. Journal of NeuroInterventional Surgery, 2014, 6, 418-422.	3.3	43
151	Trevo versus Solitaire a Headâ€toâ€Head Comparison Between Two Heavy Weights of Clot Retrieval. Journal of Neuroimaging, 2014, 24, 167-170.	2.0	40
152	Investigating the effects of double mutation C30A/C75A on onconase structure: Studies at atomic resolution. Biopolymers, 2014, 101, 454-460.	2.4	1
153	Left Atria Strain Is a Surrogate Marker for Detection of Atrial Fibrillation in Cryptogenic Strokes. Stroke, 2014, 45, e164-6.	2.0	61
154	Chemokines after human ischemic stroke: From neurovascular unit to blood using protein arrays. Translational Proteomics, 2014, 3, 1-9.	1.2	18
155	Trevo System: Single enter Experience with a Novel Mechanical Thrombectomy Device. Journal of Neuroimaging, 2013, 23, 7-11.	2.0	25
156	Arterial Blood Gas Analysis of Samples Directly Obtained Beyond Cerebral Arterial Occlusion During Endovascular Procedures Predicts Clinical Outcome. Journal of Neuroimaging, 2013, 23, 180-184.	2.0	7
157	The angiogenic gene profile of circulating endothelial progenitor cells from ischemic stroke patients. Vascular Cell, 2013, 5, 3.	0.2	18
158	1H, 13C and 15N resonance assignments of the Onconase FL-G zymogen. Biomolecular NMR Assignments, 2013, 7, 13-15.	0.8	1
159	Long-Term Treatment with Citicoline May Improve Poststroke Vascular Cognitive Impairment. Cerebrovascular Diseases, 2013, 35, 146-154.	1.7	70
160	Real-time Validation of Transcranial Doppler Criteria in Assessing Recanalization During Intra-arterial Procedures for Acute Ischemic Stroke An International, Multicenter Study. Stroke, 2013, 44, 394-400.	2.0	52
161	Difficult catheter access to the occluded vessel during endovascular treatment of acute ischemic stroke is associated with worse clinical outcome. Journal of NeuroInterventional Surgery, 2013, 5, i70-i73.	3.3	121
162	Impact of Onset-to-Reperfusion Time on Stroke Mortality. Circulation, 2013, 127, 1980-1985.	1.6	178

#	Article	IF	CITATIONS
163	Cognitive Improvement in Patients with Severe Carotid Artery Stenosis after Transcervical Stenting with Protective Flow Reversal. Cerebrovascular Diseases, 2013, 35, 124-130.	1.7	20
164	Selecting Endovascular Treatment Strategy according to the Location of Intracranial Occlusion in Acute Stroke. Cerebrovascular Diseases, 2013, 35, 502-506.	1.7	6
165	Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patients. Pharmacogenomics, 2013, 14, 495-504.	1.3	18
166	Towards Tricking a Pathogen's Protease into Fighting Infection: The 3D Structure of a Stable Circularly Permuted Onconase Variant Cleavedby HIV-1 Protease. PLoS ONE, 2013, 8, e54568.	2.5	7
167	Endovascular Treatment of Acute Ischemic Stroke. , 2013, , 131-141.		0
168	Predictors of Tissue-Type Plasminogen Activator Nonresponders According to Location of Vessel Occlusion. Stroke, 2012, 43, 417-421.	2.0	31
169	Impact of Telemedicine on Acute Management of Stroke Patients Undergoing Endovascular Procedures. Cerebrovascular Diseases, 2012, 34, 436-442.	1.7	35
170	Preferential Effect of Premorbid Statins on Atherothrombotic Strokes through Collateral Circulation Enhancement. European Neurology, 2012, 68, 171-176.	1.4	14
171	Lipoprotein-Associated Phospholipase A <sub>2</sub> Activity Is Associated with Large-Artery Atherosclerotic Etiology and Recurrent Stroke in TIA Patients. Cerebrovascular Diseases, 2012, 33, 150-158.	1.7	36
172	Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients. Stroke, 2012, 43, 1398-1400.	2.0	13
173	<i>IL1B</i> and <i>VWF</i> Variants Are Associated With Fibrinolytic Early Recanalization in Patients With Ischemic Stroke. Stroke, 2012, 43, 2659-2665.	2.0	28
174	A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. Investigational New Drugs, 2012, 30, 880-888.	2.6	19
175	A predictive clinical–genetic model of tissue plasminogen activator response in acute ischemic stroke. Annals of Neurology, 2012, 72, 716-729.	5.3	39
176	Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting. Atherosclerosis, 2012, 220, 532-536.	0.8	14
177	Generation of New Cytotoxic Human Ribonuclease Variants Directed to the Nucleus. Molecular Pharmaceutics, 2012, 9, 2894-2902.	4.6	11
178	Transcervical carotid stenting with flow reversal is a safe technique for high-risk patients older than 70 years. Journal of Vascular Surgery, 2012, 55, 978-984.	1.1	37
179	Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. Journal of Proteomics, 2012, 75, 4758-4765.	2.4	68
180	VAP-1/SSAO Plasma Activity and Brain Expression in Human Hemorrhagic Stroke. Cerebrovascular Diseases, 2012, 33, 55-63.	1.7	41

#	Article	IF	CITATIONS
181	Interactions Crucial for Three-Dimensional Domain Swapping in the HP-RNase Variant PM8. Biophysical Journal, 2011, 101, 459-467.	0.5	3
182	Antitumor Ribonucleases. Nucleic Acids and Molecular Biology, 2011, , 55-88.	0.2	5
183	Crowding agents and osmolytes provide insight into the formation and dissociation of RNase A oligomers. Archives of Biochemistry and Biophysics, 2011, 506, 123-129.	3.0	23
184	Safety and feasibility of a novel transcervical access neuroprotection system for carotid artery stenting in the PROOF Study. Journal of Vascular Surgery, 2011, 54, 1317-1323.	1.1	101
185	A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis, 2011, 216, 205-211.	0.8	103
186	Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis, 2011, 218, 181-187.	0.8	24
187	Brain Perihematoma Genomic Profile Following Spontaneous Human Intracerebral Hemorrhage. PLoS ONE, 2011, 6, e16750.	2.5	60
188	Reperfusion and Outcomes in Penumbra Vs. Systemic Tissue Plasminogen Activator Clinical Trials. International Journal of Stroke, 2011, 6, 118-122.	5.9	16
189	Thrombolysis in Anterior Versus Posterior Circulation Strokes: Timing of Recanalization, Ischemic Tolerance, and Other Differences. , 2011, 21, 108-112.		38
190	The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity. Investigational New Drugs, 2011, 29, 811-817.	2.6	13
191	A human ribonuclease induces apoptosis associated with p21WAF1/CIP1induction and JNK inactivation. BMC Cancer, 2011, 11, 9.	2.6	40
192	Extending the Time Window for Endovascular Procedures According to Collateral Pial Circulation. Stroke, 2011, 42, 3465-3469.	2.0	93
193	Validity of HAT Score for Predicting Symptomatic Intracranial Hemorrhage in Acute Stroke Patients with Proximal Occlusions: Data from Randomized Trials of Sonothrombolysis. Cerebrovascular Diseases, 2011, 31, 471-476.	1.7	10
194	Ischemic Stroke Outcome and Early Infection: Its Deleterious Effect Seems to Operate Also among Tissue Plasminogen Activator-Treated Patients. European Neurology, 2011, 65, 82-87.	1.4	8
195	Bridging Intravenous–Intra-Arterial Rescue Strategy Increases Recanalization and the Likelihood of a Good Outcome in Nonresponder Intravenous Tissue Plasminogen Activator-Treated Patients. Stroke, 2011, 42, 993-997.	2.0	64
196	Serum Low-Density Lipoprotein Cholesterol Level Predicts Hematoma Growth and Clinical Outcome After Acute Intracerebral Hemorrhage. Stroke, 2011, 42, 2447-2452.	2.0	60
197	Intraâ€arterial Administration of Microbubbles and Continuous 2â€MHz Ultrasound Insonation to Enhance Intraâ€arterial Thrombolysis. Journal of Neuroimaging, 2010, 20, 224-227.	2.0	36
198	The Proteome of Human Brain After Ischemic Stroke. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1105-1115.	1.7	43

#	Article	IF	CITATIONS
199	Safety and Efficacy of Ultrasound-Enhanced Thrombolysis. Stroke, 2010, 41, 280-287.	2.0	190
200	Oxidative Stress After Thrombolysis-Induced Reperfusion in Human Stroke. Stroke, 2010, 41, 653-660.	2.0	83
201	Reperfusion Therapy for Acute Stroke Improves Outcome by Decreasing Neuroinflammation. Translational Stroke Research, 2010, 1, 261-267.	4.2	9
202	Association of a Genetic Variant in the <i>ALOX5AP</i> with Higher Risk of Ischemic Stroke: A Case-Control, Meta-Analysis and Functional Study. Cerebrovascular Diseases, 2010, 29, 528-537.	1.7	54
203	Pattern of Response of National Institutes of Health Stroke Scale Components to Early Recanalization in the CLOTBUST Trial. Stroke, 2010, 41, 466-470.	2.0	11
204	Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke. Stroke, 2010, 41, 1528-1535.	2.0	66
205	NMR Spectroscopy Reveals that RNase A is Chiefly Denatured in 40% Acetic Acid: Implications for Oligomer Formation by 3D Domain Swapping. Journal of the American Chemical Society, 2010, 132, 1621-1630.	13.7	69
206	Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvascular Research, 2010, 80, 317-323.	2.5	69
207	KCNK17 genetic variants in ischemic stroke. Atherosclerosis, 2010, 208, 203-209.	0.8	22
208	Vertebral Artery Ultrasonography. , 2010, , 67-72.		0
209	Transcranial Doppler Sonography. , 2010, , 73-96.		1
210	Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. Thrombosis and Haemostasis, 2009, 102, 759-764.	3.4	19
211	Transcranial Duplex Sonography for Monitoring Hyperacute Intracerebral Hemorrhage. Stroke, 2009, 40, 987-990.	2.0	55
212	Endogenous Activated Protein C Predicts Hemorrhagic Transformation and Mortality after Tissue Plasminogen Activator Treatment in Stroke Patients. Cerebrovascular Diseases, 2009, 28, 143-150.	1.7	23
213	Is it Time to Reassess the SITS-MOST Criteria for Thrombolysis?. Stroke, 2009, 40, 2568-2571.	2.0	40
214	Impact of a telemedicine system on acute stroke care in a community hospital. Journal of Telemedicine and Telecare, 2009, 15, 260-263.	2.7	44
215	Mapping the stability clusters in bovine pancreatic ribonuclease A. Biopolymers, 2009, 91, 1038-1047.	2.4	5

#	Article	IF	CITATIONS
217	Buying Time for Recanalization in Acute Stroke: Arterial Blood Infusion Beyond the Occluding Clot as a Neuroprotective Strategy. Journal of Neuroimaging, 2009, 19, 188-190.	2.0	6
218	Carbodiimide EDC Induces Cross-Links That Stabilize RNase A C-Dimer against Dissociation: EDC Adducts Can Affect Protein Net Charge, Conformation, and Activity. Bioconjugate Chemistry, 2009, 20, 1459-1473.	3.6	34
219	Asymmetric Kinetics of Protein Structural Changes. Accounts of Chemical Research, 2009, 42, 778-787.	15.6	12
220	Therapeutic Interventions and Success in Risk Factor Control for Secondary Prevention of Stroke. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 460-465.	1.6	36
221	Bactericidal Activity Engineered on Human Pancreatic Ribonuclease and Onconase. Molecular Pharmaceutics, 2009, 6, 531-542.	4.6	6
222	Response to Letter by Gonzalez-Hernandez et al. Stroke, 2009, 40, .	2.0	0
223	Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome. Current Neurovascular Research, 2009, 6, 246-251.	1.1	18
224	Activation of Protein Splicing by Protease―or Lightâ€Triggered O to N Acyl Migration. Angewandte Chemie - International Edition, 2008, 47, 7764-7767.	13.8	69
225	Do Bubble Characteristics Affect Recanalization in Stroke Patients Treated with Microbubble-Enhanced Sonothrombolysis?. Ultrasound in Medicine and Biology, 2008, 34, 1573-1577.	1.5	53
226	Transcervical carotid stenting with flow reversal is safe in octogenarians: A preliminary safety study. Journal of Vascular Surgery, 2008, 47, 96-100.	1.1	31
227	Destabilizing Mutations Alter the Hydrogen Exchange Mechanism in Ribonuclease A. Biophysical Journal, 2008, 94, 2297-2305.	0.5	11
228	Distinct Unfolding and Refolding Pathways of Ribonuclease A Revealed by Heating and Cooling Temperature Jumps. Biophysical Journal, 2008, 94, 4056-4065.	0.5	22
229	A Pilot Randomized Clinical Safety Study of Sonothrombolysis Augmentation With Ultrasound-Activated Perflutren-Lipid Microspheres for Acute Ischemic Stroke. Stroke, 2008, 39, 1464-1469.	2.0	158
230	Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers. Stroke, 2008, 39, 2280-2287.	2.0	264
231	Geographic Differences in Acute Stroke Care in Catalunya: Impact of a Regional Interhospital Network. Cerebrovascular Diseases, 2008, 26, 284-288.	1.7	28
232	Progression of Symptomatic Intracranial Large Artery Atherosclerosis Is Associated With a Proinflammatory State and Impaired Fibrinolysis. Stroke, 2008, 39, 1456-1463.	2.0	89
233	Contribution of the C30/C75 disulfide bond to the biological properties of onconase. Biological Chemistry, 2008, 389, 1127-1136.	2.5	7
234	Perfusion Augmentation in Acute Stroke Using Mechanical Counter-Pulsation–Phase IIa. Stroke, 2008, 39, 2760-2764.	2.0	33

#	Article	IF	CITATIONS
235	Intracellular Routing of Cytotoxic Pancreatic-Type Ribonucleases. Current Pharmaceutical Biotechnology, 2008, 9, 169-179.	1.6	18
236	Response to Letter by Poppe et al. Stroke, 2008, 39, .	2.0	0
237	Contribution of the C30/C75 disulfide bond to the biological properties of onconase. Biological Chemistry, 2008, .	2.5	0
238	Accuracy of Serial National Institutes of Health Stroke Scale Scores to Identify Artery Status in Acute Ischemic Stroke. Circulation, 2007, 115, 2660-2665.	1.6	36
239	Speed of tPA-Induced Clot Lysis Predicts DWI Lesion Evolution in Acute Stroke. Stroke, 2007, 38, 955-960.	2.0	46
240	Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator. Stroke, 2007, 38, 1076-1078.	2.0	75
241	Patterns and Predictors of Early Risk of Recurrence After Transient Ischemic Attack With Respect to Etiologic Subtypes. Stroke, 2007, 38, 3225-3229.	2.0	204
242	Timing of Recanalization After Microbubble-Enhanced Intravenous Thrombolysis in Basilar Artery Occlusion. Stroke, 2007, 38, 2931-2934.	2.0	33
243	Clinical Deterioration After Intravenous Recombinant Tissue Plasminogen Activator Treatment. Stroke, 2007, 38, 69-74.	2.0	152
244	Transcervical carotid stenting with flow reversal protection: Experience in high-risk patients. Journal of Vascular Surgery, 2007, 46, 49-54.	1.1	38
245	MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows. Stroke, 2007, 38, 2640-2645.	2.0	249
246	Intracellular pathway of Onconase that enables its delivery to the cytosol. Journal of Cell Science, 2007, 120, 1405-1411.	2.0	55
247	Hyperglycemia during Ischemia Rapidly Accelerates Brain Damage in Stroke Patients Treated with tPA. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1616-1622.	4.3	101
248	Vertebral Artery Ultrasonography. , 2007, , 97-102.		1
249	Transcranial Doppler Sonography. , 2007, , 103-126.		1
250	Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis. Stroke, 2006, 37, 1205-1210.	2.0	90
251	Pressure-Jump-Induced Kinetics Reveals a Hydration Dependent Folding/Unfolding Mechanism of Ribonuclease A. Biophysical Journal, 2006, 91, 2264-2274.	0.5	24
252	Temporal Profile of Recanalization After Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 1000-1004.	2.0	119

#	Article	IF	CITATIONS
253	A Cytotoxic Ribonuclease Variant with a Discontinuous Nuclear Localization Signal Constituted by Basic Residues Scattered Over Three Areas of the Molecule. Journal of Molecular Biology, 2006, 360, 548-557.	4.2	22
254	ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neuroscience Letters, 2006, 398, 167-171.	2.1	23
255	Telemedicine-Guided Carotid and Transcranial Ultrasound. Stroke, 2006, 37, 229-230.	2.0	25
256	Characterization of the dimerization process of a domain-swapped dimeric variant of human pancreatic ribonuclease. FEBS Journal, 2006, 273, 1166-1176.	4.7	9
257	Stroke Patients With Cardiac Atrial Septal Abnormalities: Differential Infarct Patterns on DWI. Journal of Neuroimaging, 2006, 16, 334-340.	2.0	37
258	Pressure as a tool to study protein-unfolding/refolding processes: The case of ribonuclease A. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 461-469.	2.3	25
259	The use of pressure-jump relaxation kinetics to study protein folding landscapes. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 489-496.	2.3	22
260	The contribution of the residues from the main hydrophobic core of ribonuclease A to its pressure-folding transition state. Protein Science, 2006, 15, 1000-1009.	7.6	17
261	Thermal unfolding of eosinophil cationic protein/ribonuclease 3: A nonreversible process. Protein Science, 2006, 15, 2816-2827.	7.6	15
262	Latest advances in intracerebral hemorrhage. Current Neurology and Neuroscience Reports, 2006, 6, 17-22.	4.2	42
263	Monitoring Clot Dissolution During Intravenous Thrombolysis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 63-66.	0.3	1
264	Repeated Tissue Plasminogen Activator Treatment for Early Stroke Recurrence: Protocol Violation Is Not an Option. Stroke, 2006, 37, 1151-1153.	2.0	5
265	Increased Brain Expression of Matrix Metalloproteinase-9 After Ischemic and Hemorrhagic Human Stroke. Stroke, 2006, 37, 1399-1406.	2.0	382
266	Tandem Internal Carotid Artery/Middle Cerebral Artery Occlusion. Stroke, 2006, 37, 2301-2305.	2.0	350
267	Transcranial Doppler Monitoring of Transcervical Carotid Stenting With Flow Reversal Protection. Stroke, 2006, 37, 2846-2849.	2.0	50
268	Pressure- and temperature-induced unfolding studies: thermodynamics of core hydrophobicity and packing of ribonuclease A. Biological Chemistry, 2006, 387, 285-296.	2.5	16
269	Formation, Structure, and Dissociation of the Ribonuclease S Three-dimensional Domain-swapped Dimer Journal of Biological Chemistry, 2006, 281, 9400-9406.	3.4	26
270	Microbubble Administration Accelerates Clot Lysis During Continuous 2-MHz Ultrasound Monitoring in Stroke Patients Treated With Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 425-429.	2.0	431

#	Article	IF	CITATIONS
271	Acute Hyperglycemia State Is Associated With Lower tPA-Induced Recanalization Rates in Stroke Patients. Stroke, 2005, 36, 1705-1709.	2.0	198
272	Angiogenesis in Symptomatic Intracranial Atherosclerosis. Stroke, 2005, 36, 92-97.	2.0	52
273	Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol. Stroke, 2005, 36, 602-606.	2.0	128
274	Predictors of Early Arterial Reocclusion After Tissue Plasminogen Activator-Induced Recanalization in Acute Ischemic Stroke. Stroke, 2005, 36, 1452-1456.	2.0	199
275	On the track of antitumour ribonucleases. Molecular BioSystems, 2005, 1, 294.	2.9	69
276	Detection of Reversed Basilar Flow With Power-Motion Doppler After Acute Occlusion Predicts Favorable Outcome. Stroke, 2004, 35, 79-82.	2.0	40
277	Differential Pattern of Tissue Plasminogen Activator–Induced Proximal Middle Cerebral Artery Recanalization Among Stroke Subtypes. Stroke, 2004, 35, 486-490.	2.0	178
278	Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage. Stroke, 2004, 35, 1316-1322.	2.0	199
279	Admission Fibrinolytic Profile Is Associated With Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Tissue Plasminogen Activator. Stroke, 2004, 35, 2123-2127.	2.0	111
280	Quantitative analysis, using MALDI-TOF mass spectrometry, of the N-terminal hydrolysis and cyclization reactions of the activation process of onconase. FEBS Journal, 2004, 271, 1163-1171.	0.2	20
281	A Nuclear Localization Sequence Endows Human Pancreatic Ribonuclease with Cytotoxic Activityâ€. Biochemistry, 2004, 43, 2167-2177.	2.5	55
282	Impact of Admission Hyperglycemia on Stroke Outcome After Thrombolysis. Stroke, 2004, 35, 2493-2498.	2.0	138
283	Plasmatic Level of Neuroinflammatory Markers Predict the Extent of Diffusion-Weighted Image Lesions in Hyperacute Stroke. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1403-1407.	4.3	116
284	Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke. Circulation, 2003, 107, 598-603.	1.6	494
285	Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke. Stroke, 2003, 34, 1038-1040.	2.0	96
286	Effects of Admission Hyperglycemia on Stroke Outcome in Reperfused Tissue Plasminogen Activator–Treated Patients. Stroke, 2003, 34, 1235-1240.	2.0	235
287	Safety Profile of Tissue Plasminogen Activator Treatment Among Stroke Patients Carrying a Common Polymorphism (C-1562T) in the Promoter Region of the Matrix Metalloproteinase-9 Gene. Stroke, 2003, 34, 2851-2855.	2.0	60
288	Purification of Engineered Human Pancreatic Ribonuclease. Methods in Enzymology, 2001, 341, 221-234.	1.0	27

#	Article	IF	CITATIONS
289	Pressure versus temperature unfolding of ribonuclease A: An FTIR spectroscopic characterization of 10 variants at the carboxy-terminal site. Protein Science, 2001, 10, 725-734.	7.6	47
290	The Structure of an Engineered Domain-Swapped Ribonuclease Dimer and Its Implications for the Evolution of Proteins toward Oligomerization. Structure, 2001, 9, 967-976.	3.3	45
291	Three-dimensional structure of a human pancreatic ribonuclease variant, a step forward in the design of cytotoxic ribonucleases. Journal of Molecular Biology, 2000, 303, 49-59.	4.2	30
292	Pressure versus Heat-Induced Unfolding of Ribonuclease A:Â The Case of Hydrophobic Interactions within a Chain-Folding Initiation Siteâ€. Biochemistry, 1999, 38, 15952-15961.	2.5	80
293	Valine 108, a Chain-Folding Initiation Site-Belonging Residue, Crucial for the Ribonuclease A Stability. Biochemical and Biophysical Research Communications, 1999, 265, 356-360.	2.1	18
294	Production of Engineered Human Pancreatic Ribonucleases, Solving Expression and Purification Problems, and Enhancing Thermostability. Protein Expression and Purification, 1999, 17, 169-181.	1.3	22
295	Ribonucleases Endowed with Specific Toxicity for Spermatogenic Layers. Comparative Biochemistry and Molecular Biology, 1997, 118, 881-888.	1.6	10
296	Production of Human Pancreatic Ribonuclease inSaccharomyces cerevisiaeandEscherichia coli. Protein Expression and Purification, 1996, 7, 253-261.	1.3	9
297	Engineering ribonuclease A: production, purification and characterization of wild-type enzyme and mutants at Gln11. Protein Engineering, Design and Selection, 1995, 8, 261-273.	2.1	112
298	Approaches to Endow Ribonucleases with Antitumor Activity: Lessons Learned from the Native Cytotoxic Ribonucleases. , 0, , .		1